316 related articles for article (PubMed ID: 26293246)
21. Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors.
Liu T; Wang Z; Guo P; Ding N
Eur Biophys J; 2019 Jan; 48(1):73-82. PubMed ID: 30218115
[TBL] [Abstract][Full Text] [Related]
22. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
Pulici M; Traquandi G; Marchionni C; Modugno M; Lupi R; Amboldi N; Casale E; Colombo N; Corti L; Fasolini M; Gasparri F; Pastori W; Scolaro A; Donati D; Felder E; Galvani A; Isacchi A; Pesenti E; Ciomei M
ChemMedChem; 2015 Feb; 10(2):276-95. PubMed ID: 25430902
[TBL] [Abstract][Full Text] [Related]
23. Analyses of the oncogenic BRAF
Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z
J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109
[TBL] [Abstract][Full Text] [Related]
24. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
Oberholzer PA; Kee D; Dziunycz P; Sucker A; Kamsukom N; Jones R; Roden C; Chalk CJ; Ardlie K; Palescandolo E; Piris A; MacConaill LE; Robert C; Hofbauer GF; McArthur GA; Schadendorf D; Garraway LA
J Clin Oncol; 2012 Jan; 30(3):316-21. PubMed ID: 22067401
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and Sorafenib.
Ross FA; Hawley SA; Auciello FR; Gowans GJ; Atrih A; Lamont DJ; Hardie DG
Cell Chem Biol; 2017 Jul; 24(7):813-824.e4. PubMed ID: 28625738
[TBL] [Abstract][Full Text] [Related]
26. Structure of the Human Protein Kinase ZAK in Complex with Vemurafenib.
Mathea S; Abdul Azeez KR; Salah E; Tallant C; Wolfreys F; Konietzny R; Fischer R; Lou HJ; Brennan PE; Schnapp G; Pautsch A; Kessler BM; Turk BE; Knapp S
ACS Chem Biol; 2016 Jun; 11(6):1595-602. PubMed ID: 26999302
[TBL] [Abstract][Full Text] [Related]
27. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
Bahadoran P; Allegra M; Le Duff F; Long-Mira E; Hofman P; Giacchero D; Passeron T; Lacour JP; Ballotti R
J Clin Oncol; 2013 Jul; 31(19):e324-6. PubMed ID: 23715574
[No Abstract] [Full Text] [Related]
28. Setting up a kinase discovery and development project.
Bollag G
Curr Top Microbiol Immunol; 2012; 355():3-18. PubMed ID: 21809194
[TBL] [Abstract][Full Text] [Related]
29. Molecular basis of inactive B-RAF(WT) and B-RAF(V600E) ligand inhibition, selectivity and conformational stability: an in silico study.
Fratev F; Jónsdóttir SO; Mihaylova E; Pajeva I
Mol Pharm; 2009; 6(1):144-57. PubMed ID: 19248232
[TBL] [Abstract][Full Text] [Related]
30. In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database.
Wang ZJ; Wan ZN; Chen XD; Wu CF; Gao GL; Liu R; Shi Z; Bao JK
J Mol Model; 2015 Apr; 21(4):102. PubMed ID: 25832798
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
Tsai J; Lee JT; Wang W; Zhang J; Cho H; Mamo S; Bremer R; Gillette S; Kong J; Haass NK; Sproesser K; Li L; Smalley KS; Fong D; Zhu YL; Marimuthu A; Nguyen H; Lam B; Liu J; Cheung I; Rice J; Suzuki Y; Luu C; Settachatgul C; Shellooe R; Cantwell J; Kim SH; Schlessinger J; Zhang KY; West BL; Powell B; Habets G; Zhang C; Ibrahim PN; Hirth P; Artis DR; Herlyn M; Bollag G
Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3041-6. PubMed ID: 18287029
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis, and biological evaluation of new B-Raf
Wang PF; Zhang YJ; Wang D; Hu HM; Wang ZC; Xu C; Qiu HY; Zhu HL
Bioorg Med Chem; 2018 May; 26(9):2372-2380. PubMed ID: 29602674
[TBL] [Abstract][Full Text] [Related]
33. The phosphorylation specificity of B-RAF WT, B-RAF D594V, B-RAF V600E and B-RAF K601E kinases: an in silico study.
Fratev F; Jónsdóttir SO
J Mol Graph Model; 2010 Apr; 28(7):598-603. PubMed ID: 20093060
[TBL] [Abstract][Full Text] [Related]
34. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
35. The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.
Xie P; Streu C; Qin J; Bregman H; Pagano N; Meggers E; Marmorstein R
Biochemistry; 2009 Jun; 48(23):5187-98. PubMed ID: 19371126
[TBL] [Abstract][Full Text] [Related]
36. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
Chen SH; Zhang Y; Van Horn RD; Yin T; Buchanan S; Yadav V; Mochalkin I; Wong SS; Yue YG; Huber L; Conti I; Henry JR; Starling JJ; Plowman GD; Peng SB
Cancer Discov; 2016 Mar; 6(3):300-15. PubMed ID: 26732095
[TBL] [Abstract][Full Text] [Related]
37. Phosphorylation- and nucleotide-binding-induced changes to the stability and hydrogen exchange patterns of JNK1β1 provide insight into its mechanisms of activation.
Owen GR; Stoychev S; Achilonu I; Dirr HW
J Mol Biol; 2014 Oct; 426(21):3569-89. PubMed ID: 25178256
[TBL] [Abstract][Full Text] [Related]
38. Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.
Salerno P; De Falco V; Tamburrino A; Nappi TC; Vecchio G; Schweppe RE; Bollag G; Santoro M; Salvatore G
J Clin Endocrinol Metab; 2010 Jan; 95(1):450-5. PubMed ID: 19880792
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and characterisation of a novel type II B-RAF paradox breaker inhibitor.
Arora R; Linders JTM; Aci-Sèche S; Verheyen T; Van Heerde E; Brehmer D; Chaikuad A; Knapp S; Bonnet P
Eur J Med Chem; 2023 Mar; 250():115231. PubMed ID: 36878151
[TBL] [Abstract][Full Text] [Related]
40. Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors.
Marusiak AA; Edwards ZC; Hugo W; Trotter EW; Girotti MR; Stephenson NL; Kong X; Gartside MG; Fawdar S; Hudson A; Breitwieser W; Hayward NK; Marais R; Lo RS; Brognard J
Nat Commun; 2014 May; 5():3901. PubMed ID: 24849047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
